Catalyst Biosciences Announces Appointment of Jeanne Jew to its Board of Directors
September 08 2021 - 8:00AM
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the
appointment of Jeanne Jew to its Board of Directors.
"We are delighted to welcome Jeanne to our Board
of Directors. Jeanne’s deep corporate development expertise will be
a tremendous asset as we advance our Protease Medicines pipeline,”
said Nassim Usman, Ph.D., president and chief executive
officer of Catalyst.
Ms. Jew commented, “I look forward to supporting
the company’s continued growth and working with the team on its
strategic planning and business development initiatives. Catalyst’s
compelling and innovative portfolio of protease medicines address
areas of significant unmet medical need for patients.”
Ms. Jew brings more than 25 years of corporate
development experience to her role. She has served as the Chief
Business Officer of ALX Oncology Holdings, Inc., since August 2020.
Ms. Jew also currently serves as a QB3 Executive Mentor to
early-stage life science companies. Prior to joining ALX, she
served for over a decade as Senior Vice President, Business
Development of Paratek Pharmaceuticals, and as Senior Vice
President, Business Development for KaloBios Pharmaceuticals where
she led corporate development, strategy, and market planning. Ms.
Jew was previously Vice President, Corporate and Commercial
Development at Onyx Pharmaceuticals and was responsible for
executing the company’s co-promotion collaboration. Earlier in her
career, Ms. Jew also held business development positions at Coulter
Pharmaceutical, Scios, Inc. and Genentech, Inc. Ms. Jew holds a
B.A.in Psychology from Wesleyan University and an M.B.A. from
Cornell University.
About Catalyst Biosciences, the Protease
Medicines companyCatalyst is a research and clinical
development biopharmaceutical company focused on addressing unmet
medical needs in rare disorders of the complement and coagulation
systems. Our protease engineering platform has generated two
late-stage clinical programs, including MarzAA, a subcutaneously
(SQ) administered next-generation engineered coagulation Factor
VIIa (FVIIa) for the treatment of episodic bleeding in subjects
with rare bleeding disorders. Our complement pipeline includes a
preclinical C3-degrader program licensed to Biogen for dry
age-related macular degeneration, an improved complement factor I
protease for SQ replacement therapy in patients with CFI deficiency
and proteases from our ProTUNE™ C3b-C4b degrader and ImmunoTUNE™
C3a-C5a degrader platforms designed to target specific disorders of
the complement or inflammatory pathways as well as other complement
programs in development.
Forward-Looking StatementsThis
press release contains forward-looking statements that involve
substantial risks and uncertainties. Forward-looking statements
include, without limitation, statements about the product
candidates of Catalyst Biosciences, Inc. (the “Company”)
and the benefits of its protease engineering platform. Actual
results or events could differ materially from the plans,
intentions, expectations and projections disclosed in the
forward-looking statements. Various important factors could cause
actual results or events to differ materially, including, but not
limited to, the risk that clinical trials and pre-clinical studies
may be delayed as a result of COVID-19, competitive products and
other factors, that clinical trials may not have satisfactory
outcomes, that the Company’s complement degraders are not yet in
human clinical trials and will require additional manufacturing
validation and pre-clinical testing before entering human clinical
trials, that the Company may need to raise additional capital, and
other risks described in the "Risk Factors" section of the
Company's Annual Report on Form 10-K filed with the Securities
and Exchange Commission (the “SEC”) on March 4, 2021, the
Quarterly Report on Form 10-Q filed with the SEC
on August 5, 2021, and in other filings filed from time to
time with the SEC. The Company does not assume any obligation
to update any forward-looking statements, except as required by
law.
Contact:
Ana KaporCatalyst Biosciences,
Inc.investors@catbio.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024